drs1 Antibody

What is DRS-1 and what cellular functions does it perform?

DRS-1 (also known as ECI2, HCA88, or PECI) is an enzyme that functions as an enoyl-CoA delta isomerase. It plays a critical role in fatty acid metabolism by isomerizing both 3-cis and 3-trans double bonds into the 2-trans form in a range of enoyl-CoA species. Research indicates it has a preference for 3-trans substrates. The protein is primarily localized in the mitochondrion, consistent with its role in metabolic pathways .

What are the key characteristics of commercially available DRS-1 antibodies?

Commercial DRS-1 polyclonal antibodies are typically developed in rabbit hosts and react specifically with human DRS-1 protein (Primary Accession O75521). These antibodies are generally supplied in liquid form in PBS containing preservatives such as 50% glycerol, 0.5% BSA, and 0.09% (W/V) sodium azide. For optimal performance, they should be stored at -20°C to maintain reactivity and specificity over time .

In which tissues is DRS-1 protein most abundantly expressed?

DRS-1 shows a tissue-specific expression pattern, with particularly high abundance in metabolically active tissues including heart, skeletal muscle, and liver. Additionally, DRS-1 expression has been detected in specific immune cell populations, notably CD34(+) T-cells and CD34(+) bone marrow cells. This expression pattern aligns with its role in fatty acid metabolism, which is particularly important in tissues with high energy demands .

What are the validated applications for DRS-1 antibodies in research settings?

DRS-1 polyclonal antibodies have been validated for several experimental applications, with varying recommended dilutions:

Researchers should optimize these dilutions for their specific experimental conditions and sample types .

How can I optimize Western blot protocols when using DRS-1 antibodies?

For optimal Western blot results with DRS-1 antibodies, consider the following methodological approach:

• Use fresh lysates from tissues known to express DRS-1 (heart, skeletal muscle, liver)

• Include appropriate positive controls (e.g., recombinant DRS-1 protein)

• Optimize blocking conditions to minimize background (typically 5% non-fat milk or BSA)

• Test multiple primary antibody concentrations within the recommended range (1/500 - 1/2000)

• Include appropriate wash steps to reduce non-specific binding

• Consider the potential for cross-reactivity with related proteins given DRS-1's multiple aliases and family members

Following standardized Western blot protocols similar to those used in antibody validation studies can help ensure reproducible results .

What approaches can be used to validate the specificity of DRS-1 antibodies?

Validating antibody specificity is crucial for reliable research outcomes. Based on standardized antibody validation approaches, consider implementing:

• Knockout validation: Compare signal between wild-type and DRS-1 knockout cell lines

• Overexpression validation: Assess signal intensity in systems with controlled DRS-1 overexpression

• Peptide competition assays: Pre-incubate antibody with immunizing peptide to confirm specific binding

• Multiple antibody validation: Confirm findings using different antibodies targeting distinct epitopes of DRS-1

• Mass spectrometry correlation: Validate antibody-detected targets through orthogonal proteomic approaches

These strategies parallel validation methods used for other protein targets such as Rab1A and Rab1B in reputable studies .

What are common challenges when using DRS-1 antibodies for immunohistochemistry?

When performing immunohistochemistry with DRS-1 antibodies, researchers may encounter several challenges:

• Background staining due to high mitochondrial content in metabolically active tissues

• Variable fixation sensitivity affecting epitope accessibility

• Cross-reactivity with related isozymes in the enoyl-CoA isomerase family

• Tissue-specific expression levels affecting signal intensity

• Optimization of antigen retrieval methods for formalin-fixed tissues

To address these issues, methodically optimize antigen retrieval conditions, antibody dilutions (starting with 1/100 - 1/300), incubation times, and detection systems. Including appropriate positive controls (heart, liver tissue) and negative controls is essential for result interpretation .

How can researchers distinguish between DRS-1 and related protein family members?

Distinguishing between closely related protein family members requires careful experimental design:

• Select antibodies raised against unique epitopes specific to DRS-1

• Perform side-by-side comparisons with antibodies targeting related family members

• Include comparative analysis of knockout or knockdown systems for each family member

• Consider using dual-labeling immunofluorescence with established markers of each family member

• Combine immunodetection with functional assays specific to DRS-1's enzymatic activity

This approach is similar to the methodical discrimination between highly homologous proteins like Rab1A and Rab1B, which share 92% sequence identity but have distinct functions .

What controls should be included when using DRS-1 antibodies in immunoprecipitation experiments?

For rigorous immunoprecipitation experiments with DRS-1 antibodies, include the following controls:

• Input control: Original lysate sample before immunoprecipitation

• IgG control: Non-specific IgG from the same species as the DRS-1 antibody

• Immunodepleted lysate: Supernatant after immunoprecipitation to assess depletion efficiency

• Positive control: Lysate from tissues known to express high levels of DRS-1 (heart, skeletal muscle)

• Negative control: Lysate from cell lines with confirmed low or no expression of DRS-1

These controls parallel the standardized approach used in antibody characterization studies for other proteins, ensuring reliable interpretation of immunoprecipitation results .

How can DRS-1 antibodies be used in studies of metabolic disorders?

DRS-1's role in fatty acid metabolism makes it a potential research target in metabolic disorders:

• Expression profiling: Compare DRS-1 protein levels across normal and diseased tissues using immunohistochemistry and Western blot

• Subcellular localization studies: Investigate potential mitochondrial localization changes in disease states using immunofluorescence

• Protein-protein interaction studies: Use DRS-1 antibodies for co-immunoprecipitation to identify novel interaction partners in metabolic pathways

• Post-translational modification analysis: Combine DRS-1 immunoprecipitation with mass spectrometry to identify regulatory modifications

• Tissue microarray analysis: Assess DRS-1 expression patterns across large cohorts of patient samples

These approaches can yield insights into DRS-1's potential role in disorders involving fatty acid metabolism dysregulation .

What are the considerations for using DRS-1 antibodies in multiplexed immunofluorescence assays?

For successful multiplexed immunofluorescence with DRS-1 antibodies:

• Select compatible primary antibodies raised in different host species

• Validate spectral overlap and potential cross-reactivity between secondary antibodies

• Consider the subcellular localization of DRS-1 (mitochondrial) when selecting co-staining targets

• Optimize fixation and permeabilization conditions to preserve mitochondrial structure

• Include single-staining controls to assess bleed-through and cross-reactivity

• Use standardized image acquisition settings for quantitative comparisons

These considerations are similar to those employed in other complex immunofluorescence studies, such as those validating Rab1A/B antibodies, where knockout cell lines were used to validate specificity .

How do findings from DRS-1 knockout models inform antibody selection for specific research questions?

Findings from knockout models provide crucial insights for antibody selection:

• Epitope accessibility: Knockout studies may reveal which protein domains are most accessible for antibody binding

• Compensation effects: Upregulation of related family members in knockout models may necessitate highly specific antibodies

• Phenotype correlation: Antibodies targeting functionally significant domains may be preferred for mechanistic studies

• Tissue-specific effects: Knockout phenotypes may vary by tissue, informing tissue-specific antibody selection

• Species conservation: Cross-species knockout comparisons may guide selection of antibodies with appropriate species reactivity

This knowledge-based approach to antibody selection enhances experimental design and result interpretation in DRS-1 research .

How can DRS-1 antibodies be incorporated into single-cell analysis techniques?

Integrating DRS-1 antibodies into single-cell analysis requires specialized approaches:

• Optimization for flow cytometry: Modify fixation and permeabilization protocols for intracellular/mitochondrial staining

• Single-cell Western blot applications: Adjust antibody concentrations for microfluidic platforms

• Mass cytometry (CyTOF) adaptation: Consider metal-conjugated DRS-1 antibodies for multiplexed analysis

• Spatial transcriptomics correlation: Combine DRS-1 immunostaining with spatial RNA analysis

• Microwell-based assays: Adapt immunodetection protocols for limited cell numbers

These applications extend the utility of DRS-1 antibodies beyond traditional bulk analysis methods, enabling research at higher resolution .

What is the potential for using DRS-1 antibodies in therapeutic development research?

While DRS-1 antibodies are primarily research tools, they may contribute to therapeutic development through:

• Target validation: Confirming DRS-1's role in disease mechanisms

• Biomarker development: Establishing DRS-1 expression patterns as potential diagnostic or prognostic indicators

• Pharmacodynamic marker assessment: Monitoring DRS-1 modulation in response to therapeutic candidates

• High-throughput screening: Developing cell-based assays with DRS-1 antibodies to identify compounds affecting its function

• Mechanism of action studies: Elucidating how candidate therapeutics affect DRS-1 pathways

These applications highlight the translational potential of well-characterized research antibodies in moving from basic mechanistic understanding to therapeutic innovation .